Is repeating FOLFIRINOX in the original dosage and treatment schedule tolerable in Japanese patients with pancreatic cancer?

Publisher： John Wiley & Sons Inc

E-ISSN： 1349-7006|106|8|1100-1100

ISSN： 1347-9032

Source： Cancer Science, Vol.106, Iss.8, 2015-08, pp. : 1100-1100

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Response to Y. Sasaki et al.: Is repeating FOLFIRINOX in the original dosage and treatment schedule tolerable in Japanese patients with pancreatic cancer?

By  

Cancer Science, Vol. 106, Iss. 8, 2015-08 ,pp. : 1101-1102

John Wiley & Sons Inc

Access to resources Recommend Favorite

Presence of pancreatic intraepithelial neoplasia‐3 in a background of chronic pancreatitis in pancreatic cancer patients

By  

Cancer Science, Vol. 106, Iss. 10, 2015-10 ,pp. : 1408-1413

John Wiley & Sons Inc

Access to resources Recommend Favorite

Randomized phase II/III clinical trial of elpamotide for patients with advanced pancreatic cancer: PEGASUS‐PC Study

By  

Cancer Science, Vol. 106, Iss. 7, 2015-07 ,pp. : 883-890

John Wiley & Sons Inc

Access to resources Recommend Favorite

Subgroup analysis of Japanese patients in a phase 3 study of lenvatinib in radioiodine‐refractory differentiated thyroid cancer

By  

Cancer Science, Vol. 106, Iss. 12, 2015-12 ,pp. : 1714-1721

John Wiley & Sons Inc

Access to resources Recommend Favorite

Susceptibility of pancreatic cancer stem cells to reprogramming

By  

Cancer Science, Vol. 1347-9032, Iss. 9, 2015-09 ,pp. : 1182-1187

John Wiley & Sons Inc

Access to resources Recommend Favorite